Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas-Reference-Cited by-同舟云学术

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Published:2016-07-08 Issue:10 Volume:29 Page:1165-1172
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Scheel Andreas H^ORCID,Dietel Manfred,Heukamp Lukas C,Jöhrens Korinna,Kirchner Thomas,Reu Simone,Rüschoff Josef,Schildhaus Hans-Ulrich,Schirmacher Peter,Tiemann Markus,Warth Arne,Weichert Wilko,Fischer Rieke N,Wolf Jürgen,Buettner Reinhard

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2016117.pdf

Reference18 articles.

1. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–135.

2. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–1639.

3. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540–1550.

4. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837–1846.

5. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–2454.

Cited by 325 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pulmonary Cytopathology;Surgical Pathology Clinics;2024-09

2. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments;Virchows Archiv;2024-04

3. Predictive role of intracranial PD-L1 expression in a real-world cohort of NSCLC patients treated with immune checkpoint inhibition following brain metastasis resection;Journal of Neuro-Oncology;2024-02-15

4. Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab;American Journal of Nuclear Medicine and Molecular Imaging;2024

5. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis;The Lancet Regional Health - Europe;2024-01